Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02168907CT.gov CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01326702CT.gov Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intraocular Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bendamustine (this asset) | Wake Forest University Health Sciences | P2 | BB · 67 |
| Fludarabine | Case Comprehensive Cancer Center | P2 | BBB |
| Rituximab | Peking Union Medical College Hospital | P2 | BBB |
| Cyclophosphamide | Peking Union Medical College Hospital | P2 | BBB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BB |
| Dexasone | Peking Union Medical College Hospital | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Adriamycin | Peking Union Medical College Hospital | P2 | BB |
+42 more in the Intraocular Lymphoma cohort
Other indications for Bendamustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 70 |
| Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
| Follicular Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bendamustine in Intraocular Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/bendamustine-intraocular-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →